Logo Image

Dementia

Latest News

Jchanism/Adobe Stock
August 28th 2026
Modified Titration Dosing Reduces ARIA-E Risk With Donanemab, A Discussion With John Sims, MD

New donanemab dosing cuts ARIA-E risk, speeds MRI monitoring, and shows durable 3-year benefits with lasting biomarker gains in early Alzheimer’s.

ipopba/Adobe Stock
August 27th 2026

Biomarker Testing for Alzheimer Disease: Inside the Latest P-Tau217 Data

pipeline
May 7th 2026

Psychiatry’s Medication Pipeline in Motion

frontotemporal dementia granulin mutations PBFT02
April 20th 2026

Ongoing Trial for PBFT02 Shows Improvement of Frontotemporal Dementia With Granulin Mutations

Alzheimer blarcamesine treatment autism
April 14th 2026

Study Links Autism and Alzheimer Disease Through Shared Pathophysiology

Latest Videos

Shorts

Dementia & Benzodiazepines in Older Adults
1:50
Dementia & Benzodiazepines in Older Adults
a month ago
by
Joseph F. Goldberg, MD(+1 more)
Treating Psychosis in Dementia With Zervimesine
1:31
Treating Psychosis in Dementia With Zervimesine
5 months ago
by
Anthony Caggiano, MD, PhD
New Monoclonal Antibodies: Remternetug for Alzheimer Disease
1:46
New Monoclonal Antibodies: Remternetug for Alzheimer Disease
5 months ago
by
Matan Dabora, MD, MBA(+1 more)

CME Content

View More
Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more
Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia
Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

View more
Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

View more
(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more
Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

View more
Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia
Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

View more

More News